SELLAS Life Sciences (SLS) Equity Average (2019 - 2024)
Historic Equity Average for SELLAS Life Sciences (SLS) over the last 9 years, with Q3 2024 value amounting to $9.4 million.
- SELLAS Life Sciences' Equity Average rose 175088.58% to $9.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $9.4 million, marking a year-over-year increase of 175088.58%. This contributed to the annual value of -$1.6 million for FY2023, which is 11240.18% down from last year.
- Per SELLAS Life Sciences' latest filing, its Equity Average stood at $9.4 million for Q3 2024, which was up 175088.58% from $6.3 million recorded in Q2 2024.
- Over the past 5 years, SELLAS Life Sciences' Equity Average peaked at $31.1 million during Q2 2021, and registered a low of -$5.9 million during Q4 2023.
- Its 5-year average for Equity Average is $12.0 million, with a median of $9.0 million in 2023.
- As far as peak fluctuations go, SELLAS Life Sciences' Equity Average tumbled by 16764.67% in 2023, and later surged by 175088.58% in 2024.
- Over the past 5 years, SELLAS Life Sciences' Equity Average (Quarter) stood at $18.0 million in 2020, then skyrocketed by 30.76% to $23.5 million in 2021, then plummeted by 62.84% to $8.7 million in 2022, then tumbled by 167.65% to -$5.9 million in 2023, then skyrocketed by 259.32% to $9.4 million in 2024.
- Its Equity Average stands at $9.4 million for Q3 2024, versus $6.3 million for Q2 2024 and $854000.0 for Q1 2024.